Eli Lilly's New Obesity Pill: A Game-Changer?

Eli Lillys new obesity pill, orforglipron, shows promise in helping patients maintain significant weight loss after switching from injectable medications like Zepbound and Novo Nordisks Wegovy. The pill, which has been filed for FDA approval, could be a game-changer for long-term weight management, as it offers a convenient alternative to weekly injections. Early trial results indicate that patients who switched from Wegovy regained only about two pounds, while those transitioning from Zepbound regained around eleven pounds. This suggests the pill could be a crucial maintenance treatment, addressing a significant challenge in obesity treatment: sustaining weight loss. If approved, it could provide a much-needed, convenient option for millions globally to continue their health journey without the need for injections.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.